Drug intelligence / Profile preview

PTD988

Development stage: Preclinical
Lead developer: Pheno Therapeutics
Modality: Small Molecules

Overview

PTD988 is a preclinical-stage small molecule modulator of G-protein coupled receptor 17 (GPR17) being developed by Pheno Therapeutics. GPR17 is a key regulator of oligodendrocyte precursor cell (OPC) differentiation, acting as an endogenous 'brake' that prevents premature maturation. By targeting GPR17, PTD988 is designed to promote remyelination and restore neurological function in various demyelinating and rare neurological disorders. The drug is currently being investigated for indications including Periventricular Leukomalacia (PVL), Pelizaeus-Merzbacher Disease (PMD), Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), and Neuromyelitis Optica Spectrum Disorder (NMOSD).

Targets

LTE4R (G protein-coupled receptor 17)

Beyond the preview

Go deeper on PTD988.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTD988.

Explore the full profile